COMPARISON
EvidenceFlow vs Covidence for Systematic Reviews
Last reviewed September 14, 2026
Covidence is a widely used systematic review platform, particularly in Cochrane reviews, with a strong reputation for its screening workflow and Cochrane Risk of Bias tool. Like Rayyan, its scope stops short of statistical synthesis: Covidence's own documentation describes exporting extraction and quality-assessment data into RevMan Web (Cochrane's meta-analysis tool) for pooling, rather than pooling effect sizes itself. EvidenceFlow covers the same import-through-PRISMA workflow and continues into built-in meta-analysis, so nothing needs to be re-entered into a second tool to get a pooled result.
Feature comparison
| Feature | EvidenceFlow | Covidence |
|---|---|---|
| Title/abstract & full-text screening | Yes | Yes, by 2+ reviewers |
| Blind dual-reviewer screening | Yes, configurable reviewer count per stage | Yes, reviewers blinded to each other's votes by default |
| Conflict resolution workflow | Third reviewer, review manager, or consensus | Reviewer discussion, with a third reviewer for unresolved disagreements |
| Automatic deduplication | Yes, on import | Yes, on RIS import |
| Structured data extraction | Yes, incl. clinical + omics fields, AI auto-fill (paid) | Yes, customizable extraction templates |
| Risk-of-bias assessment | Basic fields in extraction (randomization, blinding, attrition, overall judgment) - not a structured domain-by-domain tool | Yes, Cochrane Risk of Bias tool by default, customizable |
| PRISMA 2020 flow diagram | Yes, generated automatically from screening data | Yes, generated automatically |
| Built-in meta-analysis (pooled effects, forest/funnel plots) | Yes - fixed/random effects, Mantel-Haenszel, Peto | No - exports to RevMan Web for pooling |
| Free tier / trial | Free core workflow, no time limit, no review-count cap | Free trial limited to 500 records; no ongoing free plan |
Source for Covidence's column: www.covidence.org/
Who each tool fits best
Consider EvidenceFlow if
- You want screening, extraction, PRISMA reporting, and meta-analysis in one connected workspace, without exporting data between tools.
- You want to use the core workflow indefinitely without a paid subscription.
- Your review includes genomics/omics data alongside clinical outcomes.
Consider Covidence if
- You're producing a Cochrane review and want the direct Covidence-to-RevMan Web data handoff Cochrane's own process is built around.
- You specifically need the Cochrane Risk of Bias tool as a structured, domain-by-domain assessment.
- Your team already has an annual Covidence license and an established RevMan-based analysis workflow.
Feature availability, limits, and pricing vary by plan and can change - this is a starting point for your own evaluation, not a substitute for it.
Workflow comparison
Both tools take you from imported references through blinded dual screening, conflict resolution, structured extraction, and an automatic PRISMA 2020 diagram. They diverge at analysis: Covidence's own workflow exports extraction and risk-of-bias data into RevMan Web for pooling, a well-integrated handoff but still a second tool and export step. In EvidenceFlow, the same included studies and extracted data feed directly into the built-in meta-analysis engine - import → screening → dual review → extraction → PRISMA → analysis → export happens on one dataset, in one workspace.
Pricing
EvidenceFlow
Free: import, screening, extraction, meta-analysis, and PRISMA reporting - no review limit, no seat limit.
₹399/month: adds AI-assisted screening suggestions, extraction auto-fill, and AI manuscript drafting.
Covidence
Free trial: up to 500 records, no ongoing free plan.
Single: $339/year - one review, unlimited collaborators.
Package: $907/year - up to 3 reviews, unlimited collaborators.
Organizations: custom pricing - unlimited reviews and users, 24/7 support.
Covidence pricing source: www.covidence.org/pricing/ (checked September 14, 2026). Confirm current pricing directly with Covidence before deciding.
FAQ
Is EvidenceFlow an alternative to Covidence?
For screening, extraction, and PRISMA reporting, yes - the core workflow is comparable. EvidenceFlow additionally includes built-in meta-analysis, which Covidence does not offer directly (it exports to RevMan Web); Covidence includes the Cochrane Risk of Bias tool as a structured module, which EvidenceFlow does not.
Does EvidenceFlow support blind dual review like Covidence?
Yes. You can configure how many independent reviewers are required at each screening stage and how conflicts get resolved (third reviewer, review manager, or consensus).
Can I do a full meta-analysis without leaving EvidenceFlow?
Yes - fixed and random-effects models, Mantel-Haenszel and Peto pooling, and forest/funnel plots are built in, using the same data your team extracted during screening. Covidence's own process instead exports data into RevMan Web for this step.
Which tool should a review team choose?
If you're running a Cochrane review, Covidence's direct RevMan Web integration follows Cochrane's established process closely. If you want screening through meta-analysis in one workspace without an annual per-review license, EvidenceFlow's built-in pooling is the more direct path. Feature sets and pricing on both platforms change - check each provider's current documentation before deciding.
Core import, screening, extraction, meta-analysis, and PRISMA reporting are free with no subscription or seat limits. AI-assisted screening, extraction auto-fill, and manuscript drafting are an optional paid upgrade.